Wed, Oct 1, 2014, 9:17 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

AbbVie Inc. Message Board

  • hofno2003 hofno2003 Feb 9, 2014 11:29 AM Flag

    ABBV/ENTA best in class therapy for HCV GT1b patient population, will catch 5 billion usd market share is why

    ABBV/ENTA best in class therapy for HCV GT1b patient population, will catch 5 billion usd market share is why

    ABBV/ENTA phase 3 trial for treatment naive or experienced GT1b patients showed cure rates of 100%/99% without additional ribavirin and peg-interferon. This means that we will get an FDA approval with a single tablet regimen (one tablet in the morning) for our drug in this patient group. Thats superior to GILD new drug regimen concerning the proven cure rates in this patient class of GT1b. Furthermore only ENTA has demonstrated with a separate phase 3 trial (TURQUOISE) cure rates in cirrhotic CHC patients of 96%, the most difficult to treat patient group, whereas GILD has done NO phase 3 trial on a cirrhotic patient population and has therefore no claim for this indication. So, ENTA will catch the most part of the GT1b patients and all GT1a/GT1b patients with liver cirrhosis which is quite common in this disease setting after years of CHC infection. GILD CEO admitted that ENTA will catch about 20% of overall patients, I think this was a strategic low ball statement, because the GT1b + GT1a/1b cirrhotic patients in US will represent about 50% of all initial treatment cases in US and are therefore proposed candidates for ENTAs superior treatment regimen. Superioriy can easily be figured out by comparing the P3 data of GILD and ABBV. So I bet we could and should get a 50% market share in this 10+ billion marketplace
    hofnom strong buy on ENTA, buy on ABBV

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
57.23-0.53(-0.92%)Oct 1 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Enbridge Inc.
NYSEWed, Oct 1, 2014 4:01 PM EDT
Vivint Solar, Inc.
NYSEWed, Oct 1, 2014 4:00 PM EDT
Angie's List, Inc.
NasdaqGSWed, Oct 1, 2014 4:00 PM EDT